相关实验视频

Updated: Jun 5, 2025

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"

Published on: March 31, 2021

电酶响应CRISPR系统调节的纳米炸弹用于触发电酶"自爆"研究

Wenyue Zhang¹, Ziyi Li¹, Xiaoli Lun¹

¹School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China.

ACS applied materials & interfaces

|December 16, 2024

概括

这项研究引入了一种新型纳米炸弹,该炸弹针对乳腺癌细胞中的端粒酶并抑制其,从而导致瘤切除. 这种向药物递送系统通过诱导癌细胞衰老,为癌症治疗提供了一个有希望的策略.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
癌症生物学癌症生物学

背景情况:

端粒酶是癌症进展和寿命的关键因素,使其成为癌症诊断和治疗的关键目标.
向瘤标记物,特别是端粒酶,在开发有效的癌症治疗中构成了重大挑战.
开发有针对性的药物输送系统对于精确的癌症治疗至关重要.

研究的目的:

开发一种向的纳米炸弹 (BIBR1532@HSN/FQDNA/MUC1 吸收体) 用于乳腺癌细胞中特异性抑制端粒酶.
通过使用CRISPR-Cas12a系统控制药物释放来研究瘤标记反应的"自杀"模式.
评估纳米炸弹在体外和体内瘤模型中的有效性和生物相容性.

主要方法:

用FQDNA和MUC1吸收剂功能化的空心纳米颗粒 (HSN) 的制备.
使用MUC1合体对MCF-7乳腺癌细胞进行特定向.
使用端粒酶开放剂激活的CRISPR-Cas12a系统,触发端粒酶抑制剂BIBR1532.2的释放.

主要成果:

纳米炸弹 (B@HDA) 证明了对MCF-7细胞的特定向和有效抑制端粒酶活性.
该CRISPR-Cas12a系统使BIBR1532能够准确释放,实现端粒酶"自杀",并减少非特异性药物释放.
在体内研究表明,在小鼠模型中具有良好的生物相容性和显著的瘤剥离效应.

结论:

开发的纳米炸弹提供了一个可调节的开关,用于特定的端粒酶抑制和瘤细胞生长减少.
这种方法显示了诱导癌细胞衰老的潜力,并为癌症治疗提供了一个有希望的策略.
与CRISPR技术相结合的B@HDA纳米炸弹为向癌症治疗提供了一个新且有效的平台.

关键词:

这就是CRISPR-Cas12a.癌症治疗治疗治疗癌症细胞衰老细胞衰老线粒体功能障碍线粒体功能障碍端粒酶可以自杀.

更多相关视频

Electroporation-Based CRISPR-Cas9-Mediated Gene Knockout in THP-1 Cells and Single-Cell Clone Isolation

Electroporation-Based CRISPR-Cas9-Mediated Gene Knockout in THP-1 Cells and Single-Cell Clone Isolation

Published on: February 28, 2025

CIRCLE-Seq for Interrogation of Off-Target Gene Editing

CIRCLE-Seq for Interrogation of Off-Target Gene Editing

Published on: November 1, 2024

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...

Telomeres and Telomerase

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...

Homologous Recombination

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...